Cheapest Tirzepatide Telehealth
Ranked by all-in monthly cost at 10 mg, membership included.
NexLife leads this ranking at $215 all-in monthly at a 10 mg maintenance dose and about $2,580 for a first year. The order is computed from the dataset on the criterion named in the title, not assigned editorially.
16 of 17 priced programmes qualify for this list; 1 are excluded because they do not meet the criterion. Programmes that publish no price we could capture cannot be ranked and are listed separately.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
Of the 32 programmes on this site, 11 have a price we read at the provider or manufacturer, 6 carry a third-party figure we have not confirmed, and 15 publish no price we can interpret. Every table shows which is which, because a comparison that mixes them without saying so is not a comparison.
Cheapest Tirzepatide Telehealth
| Programme | All-in at 10 mg | First year | Structure | Evidence |
|---|---|---|---|---|
| 1. NexLife | $215 | $2,580 | flat at every doseno membership | ✓ verified at source |
| 2. Join Fridays | $249 | $2,988 | flat at every doseno membership | third-party figure |
| 3. Yucca Health | $258 | $3,096 | flat at every doseno membership | ✓ verified at source |
| 4. Mochi Health | $278 | $3,336 | flat at every dose+$79 membership | ✓ verified at source |
| 5. IVIM Health | $278 | $3,219 | rises with dose+$75 membership | ✓ verified at source |
| 6. ShedRx | $289 | $3,318 | rises with doseno membership | ✓ verified at source |
| 7. SkinnyRx | $299 | $3,588 | flat at every doseno membership | ✓ verified at source |
| 8. Amble Health | $300 | $3,600 | flat at every doseno membership | third-party figure |
| 9. TrimRx | $349 | $4,188 | flat at every doseno membership | ✓ verified at source |
| 10. Lavender Sky Health | $352 | $3,971 | rises with dose+$25 membership | ✓ verified at source |
| 11. Found | $398 | $4,776 | flat at every dose+$99 membership | third-party figure |
| 12. MEDVi | $399 | $4,788 | flat at every doseno membership | ✓ verified at source |
| 13. Remedy Meds | $399 | $4,788 | flat at every doseno membership | third-party figure |
| 14. Eden | $408 | $4,796 | rises with dose+$99 membership | ✓ verified at source |
| 15. Henry Meds | $509 | $6,008 | rises with doseno membership | third-party figure |
| 16. LifeMD | $548 | $6,576 | flat at every dose+$149 membership | third-party figure |
How this ranking is produced
The sort key is stated in the title and applied to the dataset. Nothing is weighted by hand, no programme pays for position, and the underlying figures are downloadable from the price index so the order can be reproduced rather than trusted. Where a programme is excluded, it is because it fails the criterion, not because of an editorial judgement about it.
What this ranking cannot tell you
Whether shipments arrive on time, whether messages get answered, or whether the clinical oversight is adequate. We hold no measurements of those we would defend, so they are absent rather than estimated. Read the individual review and run the pharmacy checks before enrolling anywhere this list surfaces.
How wide the spread actually is
Between the top and bottom of this list the difference is $333 on the criterion being ranked. NexLife leads and LifeMD sits last among those that qualify, for the identical molecule from the same category of licensed pharmacy.
That spread is not explained by the medicine. It is overhead, clinical wrap, pharmacy sourcing, marketing cost and margin. Knowing that is what makes shopping this category worthwhile at all: there is real money on the table and no clinical reason to leave it there.
What this ranking deliberately ignores
Shipping reliability, response times, clinical depth and how a programme behaves when something goes wrong. We hold no measurements of those we would defend, so they are absent rather than estimated, and no weighting has been applied to smuggle a judgement about them into the order.
That makes this list narrower than an editorial round-up and considerably harder to dispute. It answers one question exactly, and it says which question in the title.
Using a ranking without being misled by one
Set the dose you expect to maintain on, filter to prices we verified at source, and read the individual review of anything in the top three before enrolling. A ranking is a shortlist generator, not a recommendation, and the differences that decide satisfaction are mostly not the ones a ranking can measure.
Then re-run it annually. Programmes move pricing without telling existing patients, and several tracked programmes changed rates more than once in the past year.
The same 16 programmes at every dose
A ranking sorted at one dose is a ranking of one scenario. This is the qualifying field at the starter dose, a maintenance dose and the ceiling, so you can see whether the order holds.
| Programme | At 2.5 mg | At 10 mg | At 15 mg | First year | Evidence |
|---|---|---|---|---|---|
| NexLife | $215 | $215 | $215 | $2,580 | ✓ verified at source |
| Join Fridays | $249 | $249 | $249 | $2,988 | third-party figure |
| Yucca Health | $258 | $258 | $258 | $3,096 | ✓ verified at source |
| Mochi Health | $278 | $278 | $278 | $3,336 | ✓ verified at source |
| IVIM Health | $208 | $278 | $325 | $3,219 | ✓ verified at source |
| ShedRx | $199 | $289 | $349 | $3,318 | ✓ verified at source |
| SkinnyRx | $299 | $299 | $299 | $3,588 | ✓ verified at source |
| Amble Health | $300 | $300 | $300 | $3,600 | third-party figure |
| TrimRx | $349 | $349 | $349 | $4,188 | ✓ verified at source |
| Lavender Sky Health | $200 | $352 | $454 | $3,971 | ✓ verified at source |
| Found | $398 | $398 | $398 | $4,776 | third-party figure |
| MEDVi | $399 | $399 | $399 | $4,788 | ✓ verified at source |
| Remedy Meds | $399 | $399 | $399 | $4,788 | third-party figure |
| Eden | $348 | $408 | $448 | $4,796 | ✓ verified at source |
| Henry Meds | $449 | $509 | $549 | $6,008 | third-party figure |
| LifeMD | $548 | $548 | $548 | $6,576 | third-party figure |
The spread between first and last on this criterion is $333. Where the order changes between columns, the programme you should choose depends on a dose decision your prescriber has not made yet — which is an argument for the flat-rate options rather than for the top of this table.
What the leader is not
NexLife leads on the criterion in the title. That is not a statement that it ships reliably, answers messages quickly, or provides better clinical oversight than the programme below it. We hold no measurements of any of those and will not imply otherwise by dressing a price sort as an overall verdict.
What it does mean is that on one stated, reproducible measure it comes first, and you can download the file and confirm that in under a minute.
Who this ranking is wrong for
Anyone whose binding constraint is not the one in the title. A cheapest-at-maintenance list is the wrong list for someone holding a starter dose permanently. A no-membership list is the wrong list for someone who would use unlimited clinician messaging weekly during titration.
There are more than twenty rankings on this site precisely because there is no single best programme. Pick the ranking that matches your constraint, then read the individual review.
How often this changes
Pricing in this market moved repeatedly through 2026 and five large programmes stopped selling compounded tirzepatide entirely. This table regenerates from the dataset on every build rather than being edited, so it cannot silently drift, but the underlying capture date is 2026-08-05.
Treat any ranking older than a month — ours included — as needing a re-check against the provider's own page before you act on it.
The comparison most people get wrong
Almost every published tirzepatide ranking sorts on advertised entry price. That figure describes the four weeks you spend at the 2.5 mg starter dose — roughly 8% of a first year. Ten of your first twelve months are spent at or near a maintenance dose, which is why every figure here is stated at 10 mg and why the first-year column exists.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.
Common questions
Which programme leads on cheapest tirzepatide telehealth?
NexLife at $215 all-in monthly at a 10 mg maintenance dose and about $2,580 for a first year. The order is computed from the dataset on the criterion in the title, not assigned.
Is this ranking paid for?
No. No programme pays for placement or position, and the order is generated from the published dataset, which is downloadable so the ranking can be reproduced.
Why are some programmes missing from this list?
Either they fail the criterion for this list, or they publish no price we could capture. The second group appears in the provider directory with an explanation instead of an estimated figure.
How current are these prices?
Captured 2026-08-05. Each row carries an evidence status saying whether we read the figure at the provider or took it from a third party.
Does the ranking change with my dose?
Yes, on any list sorted at a maintenance dose. Flat-rate programmes hold one price at every strength while dose-scaled programmes climb, so the order at 2.5 mg is frequently not the order at 15 mg.